Immunotherapy

Review key presentations on immunotherapy from the 2016 American Society of Clinical Oncology Annual Meeting.

Share

Program Content

Activities

  • NSCLC Anti–PD-1 Past Progression
    FDA Analysis: Metastatic NSCLC Treated With Anti–PD-1 Therapy Past RECIST Progression
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • MASTERKEY-265
    MASTERKEY-265: T-VEC + Pembrolizumab Safe, Active in Unresectable Stage IIIB/IV Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • Atezolizumab in First-line mUC
    IMvigor 210 (Cohort 1): First-line Atezolizumab in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • CTL019 Dosing in R/R ALL
    Fractionated Dosing Optimizes CAR T-Cell Therapy in Adult Relapsed/Refractory ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • Atezolizumab in Pretreated mUC
    IMvigor 210 (Cohort 2): Atezolizumab in Pretreated Metastatic Urothelial Carcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • Atezolizumab in mTNBC
    Atezolizumab + Nab-Paclitaxel Well Tolerated and Active in Metastatic TNBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2016

    Expires: June 06, 2017

  • Pembrolizumab in R/R MM
    KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2016

    Expires: June 07, 2017

  • Pembrolizumab in Advanced CC
    KEYNOTE-028: Pembrolizumab in PD-L1+ Advanced Cervical Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2016

    Expires: June 08, 2017

  • Pembrolizumab in MMRD CRC
    Pembrolizumab Shows Promising Activity in Mismatch Repair–Deficient CRC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2016

    Expires: June 08, 2017

  • Nivo Beyond Progression in RCC
    Potential Benefit of Nivolumab Treatment Beyond Progression in Advanced RCC: Subgroup Analysis of CheckMate 025
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2016

    Expires: June 08, 2017

  • MEK/PD-L1 Combo in mCRC
    Cobimetinib + Atezolizumab Well Tolerated and Shows Promising Activity in KRAS-Mutant mCRC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2016

    Expires: June 09, 2017

  • Pembrolizumab in Melanoma
    KEYNOTE-006: Final OS Analysis of Pembrolizumab vs Ipilimumab for Advanced Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2016

    Expires: June 12, 2017

  • Pembro + Ipili in Advanced Melanoma
    KEYNOTE-029 Expansion Cohort: Pembrolizumab + Ipilimumab Safe, Active in Advanced Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2016

    Expires: June 13, 2017

  • Immunoscore in CRC
    Immunoscore Prognostic in Colon Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2016

    Expires: June 13, 2017

  • Atezolizumab Predictors of Response
    IMvigor210: Predictors of Response to Atezolizumab in mUC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2016

    Expires: June 13, 2017

  • Downloadable Slideset
    Immunotherapy: A Review of Key Clinical Studies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 19, 2016

    Expires: September 18, 2017

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals